ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial

ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial

Source: 
Fierce Pharma
snippet: 

Sometimes in oncology, where both the unmet need and the level of competition are high, when you see a signal, you go for it. Taking on a bit more risk to head into phase 3 can make sense "because the patients are waiting and the business opportunity is in front of you,” as one Pfizer exec put it.